Novo Nordisk is doing big business with weight loss injections: the Danish company’s market value has tripled since 2020 and was now at 400 billion euros. This meant the company was worth more than the Danish national budget or the leading German car brands combined. The market for these syringes is huge and the company can hardly meet the demand.
Novo Nordisk donates generously to specialist associations in the diabetes and obesity sector in Germany, organizes conferences and finances studies. Jens Aberle, head of the German Obesity Society, also received money from the company, but did not make this transparent. There is a “potential conflict of interest,” criticizes Berit Uhlmann from the SZ knowledge department after joint research with NDR and WDR.
This is how you can subscribe to our research podcast:
“The topic” is the research podcast from the Süddeutsche Zeitung. The Podcast usually appears every two weeks. You can find all episodes at sz.de/dasthema. Don’t miss an episode and subscribe to our audio offering in your favorite podcast app, for example Apple Podcasts or Spotify. You can find an overview of all our podcasts at www.sz.de/podcast and Here you can find out how you can listen to our podcasts. If you like “The Topic”, if you have suggestions, ideas or criticism for us, then write to us: [email protected].